Detalhe da pesquisa
1.
Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin-treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial.
Diabetes Obes Metab
; 23(6): 1221-1231, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33606908
2.
Advancing Therapy in Suboptimally Controlled Basal Insulin-Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial.
Diabetes Care
; 2021 Jun 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34183429
3.
Improvement in the management of chronic heart failure since the publication of the updated guidelines of the European Society of Cardiology. The Impact-Reco Programme.
Eur J Heart Fail
; 11(1): 85-91, 2009 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19147461
4.
Equal improvement in glycaemia with lixisenatide given before breakfast or the main meal of the day.
J Diabetes Complications
; 28(5): 735-41, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25012990
5.
First evaluation using a validated scale of the risk of congestive heart failure among hypertensive patients treated by general practitioners (O-PREDICT survey).
Arch Cardiovasc Dis
; 103(3): 176-83, 2010 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-20417449
6.
Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B/apolipoprotein A-1 ratio in patients with acute coronary syndrome: results of the CENTAURUS study.
Arch Cardiovasc Dis
; 103(3): 160-9, 2010 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-20417447